136 related articles for article (PubMed ID: 38258325)
21. Association between migraine prevalence, treatment with proton-pump inhibitors and CYP2C19 phenotypes in UK Biobank.
Pisanu C; Welander NZ; Rukh G; Schiöth HB; Mwinyi J
Biomed Pharmacother; 2021 Nov; 143():112234. PubMed ID: 34649359
[TBL] [Abstract][Full Text] [Related]
22. The proton pump inhibitor lansoprazole, but not rabeprazole, the increased blood concentrations of calcineurin inhibitors in Japanese patients with connective tissue diseases.
Isoda K; Takeuchi T; Kotani T; Hirano-Kuwata S; Shoda T; Hata K; Yoshida S; Makino S; Hanafusa T
Intern Med; 2014; 53(13):1413-8. PubMed ID: 24990333
[TBL] [Abstract][Full Text] [Related]
23. Influence of lansoprazole and rabeprazole on mycophenolic acid pharmacokinetics one year after renal transplantation.
Miura M; Satoh S; Inoue K; Kagaya H; Saito M; Suzuki T; Habuchi T
Ther Drug Monit; 2008 Feb; 30(1):46-51. PubMed ID: 18223462
[TBL] [Abstract][Full Text] [Related]
24. Comparison of acid inhibition with standard dosages of proton pump inhibitors in relation to CYP2C19 genotype in Japanese.
Sugimoto M; Shirai N; Nishino M; Kodaira C; Uotani T; Sahara S; Ichikawa H; Kagami T; Sugimoto K; Furuta T
Eur J Clin Pharmacol; 2014 Sep; 70(9):1073-8. PubMed ID: 24996380
[TBL] [Abstract][Full Text] [Related]
25. Effects of proton pump inhibitors, esomeprazole and vonoprazan, on the disposition of proguanil, a CYP2C19 substrate, in healthy volunteers.
Funakoshi R; Tomoda Y; Kudo T; Furihata K; Kusuhara H; Ito K
Br J Clin Pharmacol; 2019 Jul; 85(7):1454-1463. PubMed ID: 30845361
[TBL] [Abstract][Full Text] [Related]
26. Vonoprazan, a Novel Potassium-Competitive Acid Blocker, Should Be Used for the Helicobacter pylori Eradication Therapy as First Choice: A Large Sample Study of Vonoprazan in Real World Compared with Our Randomized Control Trial Using Second-Generation Proton Pump Inhibitors for Helicobacter pylori Eradication Therapy.
Ozaki H; Harada S; Takeuchi T; Kawaguchi S; Takahashi Y; Kojima Y; Ota K; Hongo Y; Ashida K; Sakaguchi M; Tokioka S; Sakamoto H; Furuta T; Tominaga K; Higuchi K
Digestion; 2018; 97(3):212-218. PubMed ID: 29393194
[TBL] [Abstract][Full Text] [Related]
27. Randomized Trial Comparing Esomeprazole and Rabeprazole in First-line Eradication Therapy for Helicobacter pylori Infection based on the Serum Levels of Pepsinogens.
Shimoyama T; Chinda D; Sawada Y; Komai K; Chiba H; Saito Y; Sasaki Y; Matsuzaka M; Fukuda S
Intern Med; 2017; 56(13):1621-1627. PubMed ID: 28674348
[TBL] [Abstract][Full Text] [Related]
28. CYP2C19 pharmacogenomics associated with therapy of Helicobacter pylori infection and gastro-esophageal reflux diseases with a proton pump inhibitor.
Furuta T; Sugimoto M; Shirai N; Ishizaki T
Pharmacogenomics; 2007 Sep; 8(9):1199-210. PubMed ID: 17924835
[TBL] [Abstract][Full Text] [Related]
29. Effect of lansoprazole and rabeprazole on tacrolimus pharmacokinetics in healthy volunteers with CYP2C19 mutations.
Itagaki F; Homma M; Yuzawa K; Nishimura M; Naito S; Ueda N; Ohkohchi N; Kohda Y
J Pharm Pharmacol; 2004 Aug; 56(8):1055-9. PubMed ID: 15285851
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and tolerability of first-line triple therapy with levofloxacin and amoxicillin plus esomeprazole or rabeprazole for the eradication of Helicobacter pylori infection and the effect of CYP2C19 genotype: a 1-week, randomized, open-label study in Chinese adults.
Pan X; Li Y; Qiu Y; Tang Q; Qian B; Yao L; Shi R; Zhang G
Clin Ther; 2010 Nov; 32(12):2003-11. PubMed ID: 21118735
[TBL] [Abstract][Full Text] [Related]
31. Comparison of the kinetic disposition of and serum gastrin change by lansoprazole versus rabeprazole during an 8-day dosing scheme in relation to CYP2C19 polymorphism.
Ieiri I; Kishimoto Y; Okochi H; Momiyama K; Morita T; Kitano M; Morisawa T; Fukushima Y; Nakagawa K; Hasegawa J; Otsubo K; Ishizaki T
Eur J Clin Pharmacol; 2001 Sep; 57(6-7):485-92. PubMed ID: 11699613
[TBL] [Abstract][Full Text] [Related]
32. The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: a meta-analysis.
Padol S; Yuan Y; Thabane M; Padol IT; Hunt RH
Am J Gastroenterol; 2006 Jul; 101(7):1467-75. PubMed ID: 16863547
[TBL] [Abstract][Full Text] [Related]
33. Lansoprazole Is Associated with Worsening Asthma Control in Children with the CYP2C19 Poor Metabolizer Phenotype.
Lang JE; Holbrook JT; Mougey EB; Wei CY; Wise RA; Teague WG; Lima JJ;
Ann Am Thorac Soc; 2015 Jun; 12(6):878-85. PubMed ID: 25844821
[TBL] [Abstract][Full Text] [Related]
34. Enantioselective disposition of lansoprazole and rabeprazole in human plasma.
Miura M
Yakugaku Zasshi; 2006 Jun; 126(6):395-402. PubMed ID: 16755125
[TBL] [Abstract][Full Text] [Related]
35. CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole.
Adachi K; Katsube T; Kawamura A; Takashima T; Yuki M; Amano K; Ishihara S; Fukuda R; Watanabe M; Kinoshita Y
Aliment Pharmacol Ther; 2000 Oct; 14(10):1259-66. PubMed ID: 11012469
[TBL] [Abstract][Full Text] [Related]
36. Effects of CYP2C19 loss-of-function variants on the eradication of H. pylori infection in patients treated with proton pump inhibitor-based triple therapy regimens: a meta-analysis of randomized clinical trials.
Tang HL; Li Y; Hu YF; Xie HG; Zhai SD
PLoS One; 2013; 8(4):e62162. PubMed ID: 23646118
[TBL] [Abstract][Full Text] [Related]
37. Concomitant Proton Pump Inhibitors and Immune Checkpoint Inhibitors Increase Nephritis Frequency.
Kato K; Mizuno T; Koseki T; Ito Y; Hatano M; Takahashi K; Yamada S; Tsuboi N
In Vivo; 2021; 35(5):2831-2840. PubMed ID: 34410975
[TBL] [Abstract][Full Text] [Related]
38. New-generation proton pump inhibitors: overcoming the limitations of early-generation agents.
Robinson M
Eur J Gastroenterol Hepatol; 2001 May; 13 Suppl 1():S43-7. PubMed ID: 11430508
[TBL] [Abstract][Full Text] [Related]
39. Associations of proton pump inhibitors and hospitalization due to hyponatremia: A population-based case-control study.
Falhammar H; Lindh JD; Calissendorff J; Skov J; Nathanson D; Mannheimer B
Eur J Intern Med; 2019 Jan; 59():65-69. PubMed ID: 30154038
[TBL] [Abstract][Full Text] [Related]
40. Influences of different proton pump inhibitors on the anti-platelet function of clopidogrel in relation to CYP2C19 genotypes.
Furuta T; Iwaki T; Umemura K
Br J Clin Pharmacol; 2010 Sep; 70(3):383-92. PubMed ID: 20716239
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
